¼¼°èÀÇ ÇöóÁ ¼ö¼ú ½ÃÀå
Plasma Surgery
»óǰÄÚµå : 1793725
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 365 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

ÇöóÁ ¼ö¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 9,100¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6,950¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇöóÁ ¼ö¼ú ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 9,100¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 4.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ´ºÆ®·² ÇöóÁ ¼ö¼ú ½Ã½ºÅÛÀº CAGR 5.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 6,020¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇöóÁ ÀýÁ¦ ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1,890¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇöóÁ ¼ö¼ú ½ÃÀåÀº 2024³â¿¡´Â 1,890¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö CAGR 8.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 1,900¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.9%¿Í 3.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÇöóÁ ¼ö¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çö´ë ¿Ü°ú Áø·á¿¡¼­ Àú¿Â ÇöóÁ¿Í ¿­ ÇöóÁÀÇ º¯ÇõÀû ¿ªÇÒ¿¡ ´ëÇÑ Å½±¸

ÇöóÁ ¼ö¼úÀÌ ÃÖ¼Òħ½À Ä¡·áÀÇ »õ·Î¿î °³Ã´ÀÚ°¡ µÉ ¼ö ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÇöóÁ ¼ö¼úÀº Á¤¹ÐÇÑ Á¶Á÷ Á¶ÀÛ, ÀÀ°í, ÀýÁ¦ µîÀ» À§ÇØ ÀÌ¿ÂÈ­ °¡½º ÇöóÁ¸¦ Àû¿ëÇÏ¿© ¿Ü°ú ¼ö¼ú¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­´Â ÄÝµå ¾ÆÅä¸ð½ºÇǾî ÇöóÁ(CAP)¿Í ¿­ ÇöóÁ ½Ã½ºÅÛÀ̶ó´Â µÎ °¡Áö ÁÖ¿ä ±â¼úÀÌ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. Àú¿Â ÇöóÁ´Â »ó¿Â¿¡¼­ ÀÛµ¿Çϱ⠶§¹®¿¡ ¾È°ú³ª ÇǺΰú¿Í °°Àº ¼¶¼¼ÇÑ ¼ö¼ú¿¡ ºñ¿­Àû Àû¿ëÀÌ °¡´ÉÇÕ´Ï´Ù. ÇÑÆí, ½á¸Ö ÇöóÁ´Â Á¤Çü¿Ü°ú, À̺ñÀÎÈİú µîÀÇ ¿µ¿ª¿¡¼­ ÀÀ°í ¹× ÀýÁ¦¼ú¿¡ ÀûÇÕÇÑ °í¿ÂÀ» ¹ß»ý½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ´Ù¾çÇÑ ¹æ¹ýÀº ±¤¹üÀ§ÇÑ ºÎ¼öÀû ¼Õ»ó ¾øÀÌ Á¤È®ÇÑ Á¶Á÷ Ç¥ÀûÀ» Á¦°øÇÔÀ¸·Î½á ÇöóÁ ½Ã½ºÅÛÀ» Àü±â ¸Þ½º, ·¹ÀÌÀú, °íÁÖÆÄÀÇ ´ë¾È°ú Â÷º°È­ÇÕ´Ï´Ù. ±âÁ¸ÀÇ ¿¡³ÊÁö ±â¹Ý ÀåÄ¡¿Í ´Þ¸® ÇöóÁ ¸Þ½º³ª ÀýÁ¦±â´Â »ó´çÈ÷ ³ôÀº ¼ö¼ú Á¤È®µµ¿Í ¿­ È®»ê °¨¼Ò¸¦ ½ÇÇöÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, Æíµµ¼± ÀýÁ¦¼úÀ̳ª ¾Æµ¥³ëÀ̵å ÀýÁ¦¼ú°ú °°Àº ¼ö¼ú¿¡¼­ ÇöóÁ ¸Þ½º´Â ¼ö¼ú Áß ÃâÇ÷°ú ¼ö¼ú ÈÄ ÅëÁõÀ» °¨¼Ò½ÃŰ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. Àý°³¿Í ÀÀ°í¸¦ ÇÑ ¹ø¿¡ ÇÒ ¼ö ÀÖ´Â ÇöóÁ ¸Þ½º´Â À̺ñÀÎÈİú, ½Å°æ¿Ü°ú, »êºÎÀΰú, ºñ´¢±â°ú¿¡¼­ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌÆú¶ó ÇöóÁ ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¶Á÷ÀÇ ÀÓÇÇ´ø½º¿¡ µû¶ó ½Ç½Ã°£À¸·Î ¿¡³ÊÁö °ø±ÞÀ» Á¶ÀýÇÒ ¼ö ÀÖ°Ô µÇ¾î ¼ö¼ú Áß Á¦¾î°¡ ´õ¿í °­È­µÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ »óó Ä¡À¯ °³¼±, ¿°Áõ ¹ÝÀÀ °¨¼Ò, ȸº¹ ½Ã°£ ´ÜÃàÀÌ °è¼Ó °­Á¶µÇ°í ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ ´õ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÇöóÁ ¼ö¼ú ½Ã½ºÅÛÀÌ °¡Àå ¸¹ÀÌ º¸±ÞµÈ °÷Àº ¾îµðÀΰ¡?

ÇöóÁ ¼ö¼ú ÀåºñÀÇ ÀÓ»ó µµÀÔÀº ´Ù¾çÇÑ ¼ö¼ú Àü¹® ºÐ¾ß¿¡ ´ëÇÑ ÀûÇÕ¼º¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. À̺ñÀÎÈİú(ENT)´Â ÇöóÁ ±â¼úÀ» °¡Àå ¸ÕÀú µµÀÔÇÑ ºÐ¾ß Áß Çϳª·Î, ºñ°©°³ Ãà¼Ò¼ú, Æíµµ¼± ÀýÁ¦¼ú, ¿ëÁ¾ ÀýÁ¦¼ú µîÀÇ ½Ã¼ú¿¡¼­ ÇöóÁ ±â¼úÀÇ ÀúÃâÇ÷ ÇÁ·ÎÆÄÀÏÀÌ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ºÎÀΰú ¿µ¿ª¿¡¼­µµ ÇöóÁ¸¦ ÀÌ¿ëÇÑ Àڱ󻸷 ¼ÒÀÛ¼úÀ̳ª º¹°­°æ ¼ö¼ú, ƯÈ÷ ¿­ ¼Õ»óÀÌ ±Ý±âÀΠȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ º¹°­°æ ¼ö¼úÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ °í¼ºÀå ºÐ¾ß´Â Á¤Çü¿Ü°ú ¹× ôÃß ¼ö¼ú ºÐ¾ß·Î, ÇöóÁ ÁöÆÎÀ̰¡ ¿¬ºÎÁ¶Á÷ÀÇ È¿À²ÀûÀÎ Á¦°Å¿Í ¹Î°¨ÇÑ ½Å°æ ±¸Á¶¹° ÁÖº¯ÀÇ Á¤È®ÇÑ ÀÀ°í¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ºÐ¾ßÀÔ´Ï´Ù. Á¾¾çÇÐ ºÐ¾ß¿¡¼­´Â ƯÈ÷ ±âÀú¼¼Æ÷¾ÏÀ̳ª ÆíÆò»óÇǾϰú °°Àº Ç¥À缺 ¾ÏÀ» ´ë»óÀ¸·Î Á¾¾ç Ãà¼Ò¸¦ À§ÇÑ Àú¿Â ÇöóÁ ÀÀ¿ë ¿¬±¸°¡ ½ÃÀ۵ǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¼úÀÇ Á¤È®¼ºÀÌ °¡Àå Áß¿äÇÑ ½Å°æ¿Ü°ú¿¡¼­´Â ÁÖº¯ Á¶Á÷ÀÇ ¹«°á¼ºÀ» À¯ÁöÇϸ鼭 ³ú½Å°æ ºÎÀ§ÀÇ Á¾¾çÀ» ºÐ¸®Çϱâ À§ÇØ Àú¿Â ÇöóÁ ½Ã½ºÅÛÀÌ ½ÃÇèÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì¿ë¿Ü°ú³ª ÇǺΰú ºÐ¾ß¿¡¼­µµ ÇǺΠǥ¸é ó¸®, ¿©µå¸§ ÈäÅÍ Ä¡·á, ºñÀýÁ¦½Ä ÇǺΠȸÃáÀ» À§ÇØ ÇöóÁ ÆæÀÇ µµÀÔÀÌ ºü¸£°Ô ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ¼¼°è ÇöóÁ ¼ö¼ú ½ÃÀåÀ» ÁÖµµÇϰí Àִµ¥, ÀÌ´Â ¼±ÁøÈ­µÈ ÇコÄɾî ÀÎÇÁ¶ó, ³ôÀº ½Ã¼ú·®, Medtronic, Smith &Nephew, Bovie Medical°ú °°Àº À¯·Â ±â¾÷ÀÇ Á¸Àç¿¡ ±âÀÎÇÕ´Ï´Ù. ƯÈ÷ µ¶Àϰú ¿µ±¹¿¡¼­´Â À̺ñÀÎÈİú¿Í ºÎÀΰú »ç¿ë »ç·Ê°¡ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ¾ÆÁ÷ ½ÃÀÛ ´Ü°èÀÌÁö¸¸, ¼ö¼ú °Ç¼ö Áõ°¡, ¹Î°£ º´¿øÀÇ Áõ°¡, ÇǺΰú ¹× Á¾¾çÇÐ ºÐ¾ßÀÇ ºñ¿­ ÇöóÁ ÀÀ¿ë¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. Çѱ¹À̳ª Àεµ¿Í °°Àº ±¹°¡µéÀº ºñ¿ëÀÇ Á¦¾à°ú ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä·Î ÀÎÇØ ÈÞ´ë¿ë ÇÚµåÇïµå ÇöóÁ ÀåºñÀÇ Ãʱ⠵µÀÔ ±¹°¡·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ÇöóÁ ±â¹Ý ¼ö¼ú ±â¼úÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ÇöóÁ ¼ö¼ú ÀÀ¿ëÀÇ È®ÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ±âµÕÀÔ´Ï´Ù. ÃÖ±ÙÀÇ Çõ½ÅÀº ÇöóÁ ÀåÄ¡ÀÇ ¼ÒÇüÈ­¸¦ ÅëÇØ ·Îº¿ ¼ö¼ú¿ë ¾ÏÀ̳ª À¯¿¬ÇÑ ³»½Ã°æ Ç÷§Æû¿¡ ÅëÇÕÇÒ ¼ö ÀÖ°Ô µÈ °ÍÀÔ´Ï´Ù. ÀÌ °³¹ßÀº µÎ°³ ³», ±â°üÁö, ¼ÒÈ­°ü µî Á¢±ÙÇϱ⠾î·Á¿î ÇØºÎÇÐÀû ¿µ¿ª¿¡ Á¢±ÙÇÏ´Â µ¥ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. Àú¿Â ÇöóÁ ½Ã½ºÅÛ°ú ±¤¼¶À¯ Àü´Þ ¸ðµâÀÇ °áÇÕÀ¸·Î ±â°üÁö ³» ¼ÒÀÛ¼ú, ºñ°­³» ÁßÀç¼ú°ú °°Àº ³»½Ã°æ ¼ö¼ú¿¡¼­ º¸´Ù ¾ÈÀüÇϰí Ç¥ÀûÈ­µÈ ÇöóÁ Àû¿ëÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, »ý¹°ÇÐÀû À¯Ã¼¸¦ ÀÌ¿ÂÈ­ÇÑ ÈÄ Á¶Á÷¿¡ Àû¿ëÇÏ´Â ÇöóÁ Ȱ¼ºÈ­ ¸Åü(PAM)¿¡ ´ëÇÑ ¿¬±¸µµ ºü¸£°Ô ÁøÇàµÇ°í ÀÖÀ¸¸ç, Á÷Á¢ Á¢ÃËÇÏÁö ¾Ê°íµµ »ì±Õ ¹× ¾Ï¼¼Æ÷ÀÇ ¼¼Æ÷ »ç¸êÀ» À¯µµÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ Á¢±Ù¹ýÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. AI¿Í ½Ç½Ã°£ ºÐ¼®ÀÇ ÅëÇÕµµ Â÷¼¼´ë ÇöóÁ ½Ã½ºÅÛ¿¡¼­ µîÀåÇϱ⠽ÃÀÛÇß½À´Ï´Ù. Á¶Á÷ÀÇ Çǵå¹é¿¡ µû¶ó ¿¡³ÊÁö Ãâ·ÂÀ» Á¶Á¤ÇÏ´Â ¾Ë°í¸®ÁòÀº ¾ÈÀü¼ºÀ» ³ôÀÌ°í ¼ö¼ú Áß ÃßÃøÀ» ÁÙ¿©ÁÝ´Ï´Ù. Àç·á°úÇÐ Ãø¸é¿¡¼­´Â »ýüÀûÇÕ¼º Àü±Ø ÄÚÆÃ°ú °íÁÖÆÄ º¯Á¶ ȸ·ÎÀÇ °³¹ß·Î ÀûÀÀ È®´ë¿¡ ÇʼöÀûÀÎ ¾ÆÅ© Çü¼º ¹× Ãâ·Â ¹Ðµµ Á¦¾î°¡ °¡´ÉÇØÁ³½À´Ï´Ù.

Çϵå¿þ¾îÀÇ Çõ½Å°ú ´õºÒ¾î »ç¿ëÀÚ ÀÎÅÍÆäÀ̽º¿Í ½Ã¼ú ÅÛÇø´ÀÇ ¼ÒÇÁÆ®¿þ¾î Áß½ÉÀÇ ¹ßÀüÀº ÇöóÁ Àåºñ¸¦ º¸´Ù ¿Ü°ú ÀÇ»ç ģȭÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÌ Àåºñ´Â ÇöÀç ÅÍÄ¡ ½ºÅ©¸° Á¶ÀÛ, »çÀü ÇÁ·Î±×·¡¹Ö µÈ ½Ã¼ú ¸ðµå ¹× º´¿ø EHR°úÀÇ ÅëÇÕÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â´ÉÀ» ÅëÇØ Àåºñ ±³À°ÀÌ °£¼ÒÈ­µÇ°í, ½Ã¼ú °á°ú°¡ Ç¥ÁØÈ­µÇ¸ç, ¿Ü·¡ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, ÀÇ·á±â±â Á¦Á¶¾÷ü, ÀÓ»ó ¿¬±¸ÀÚ, ÇÐ°è µî ¾÷°è °£ Çù·ÂÀº º¸´Ù °ß°íÇÑ ÀÓ»ó ÇÁ·ÎÅäÄݰú ¾ÈÀü¼º º¥Ä¡¸¶Å©¸¦ È®¸³ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖÀ¸¸ç, ±ÔÁ¦ ´ç±¹ÀÇ ½Å¼ÓÇÑ ½ÂÀΰú ½ÅÈï±¹ ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼¼°è ÇöóÁ ¼ö¼úÀÇ ºÎ»óÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ½ÃÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼°è ÇöóÁ ¼ö¼ú ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú, ÀÓ»ó, ±ÔÁ¦, °æÁ¦ µî ¿©·¯ ºÐ¾ß¿¡ °ÉÄ£ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â °ÅÀÇ ¸ðµç ¼ö¼ú Àü¹® ºÐ¾ß¿¡¼­ ÃÖ¼Òħ½À¼ö¼ú(MIS) ±â¼úÀÌ ¼±È£µÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¿Ü°ú ÀÇ»ç¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â ÀÔ¿ø ½Ã°£, ÇÕº´Áõ ¹× Àüü ½Ã¼ú ºñ¿ëÀ» ÁÙÀÌ´Â Àú¿Ü»ó¼º °³ÀÔÀ¸·Î ÀüȯÇϰí ÀÖÀ¸¸ç, ÇöóÁ ¼ö¼úÀÌ Æ¯È÷ ÀûÇÕÇÑ ºÐ¾ßÀÔ´Ï´Ù. ÇöóÁ ½Ã½ºÅÛÀº È¿°úÀûÀÎ ÁöÇ÷, °¡½Ã¼º Çâ»ó, ȸº¹ ½Ã°£ ´ÜÃàÀ» °¡´ÉÇÏ°Ô Çϸç, ÀÌ ¸ðµç °ÍÀÌ ¼ö¼ú 󸮷®À» °¡¼ÓÈ­Çϰí ȯÀÚ ¸¸Á·µµ¸¦ Çâ»ó½ÃŰ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ƯÈ÷ ¹Ì±¹, ÀϺ», Àεµ¿¡¼­ ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)ÀÇ ¼¼°è È®´ë°¡ ÁøÇà ÁßÀÎ °Íµµ È£Àç·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯°æ¿¡¼­´Â ¼ÒÇü, ´Ù±â´É, ³ôÀº ¾ÈÀü ¸¶ÁøÀ» °¡Áø ±â±â°¡ ¿ä±¸µË´Ï´Ù. ¶ÇÇÑ, ³ë·ÉÀα¸ÀÇ Áõ°¡¿Í ¾Ï, ÀڱñÙÁ¾, ÄÚ Æú¸³, °ñ°üÀý¿° µî ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ´ú ħ½ÀÀûÀ̰í È¿°úÀûÀÎ ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇöóÁ ¼ö¼úÀº ÀÌ·¯ÇÑ »óȲ¿¡¼­, ƯÈ÷ ±âÁ¸ Ä¡·á¹ýÀÌ ³Ê¹« À§ÇèÇϰųª ¿À·£ ±â°£ÀÇ ÀçȰÀÌ ÇÊ¿äÇÑ °æ¿ì ½Å·ÚÇÒ ¼ö ÀÖ´Â ´ë¾ÈÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¸ð¸àÅÒÀº º¸´Ù À¯¸®ÇÑ ±ÔÁ¦ »óȲ°ú »óȯ ÇÁ·¹ÀÓ¿öÅ©¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ÇǺΰú ¹× À̺ñÀÎÈİú ¼ö¼ú¿¡¼­ ƯÁ¤ Àú¿Â ÇöóÁ Àû¿ëÀº ÇöÀç ¹Ì±¹ ¹× µ¶ÀÏ¿¡¼­ °ø°ø ¹× ¹Î°£ º¸Çèȸ»ç¿¡¼­ º¸Çè Àû¿ëÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä Àåºñ Á¦Á¶¾÷üÀÇ ¿¬±¸°³¹ß, Á¦Ç° ±³À°, ¼¼°è ´ë¸®Á¡ ³×Æ®¿öÅ©¿¡ ´ëÇÑ Àü·«Àû ÅõÀÚ°¡ ½ÃÀå ħÅõ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó °ËÁõÀ» À§ÇÑ Çмú ±â°ü°úÀÇ Çù·ÂÀ» ÅëÇØ ÇöóÁ ±â¼úÀ» Ç¥ÁØ Ä¡·á¿¡ ºü¸£°Ô ÅëÇÕÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ÀüÅëÀûÀÎ Àü±â ¼ö¼ú¿¡ µû¸¥ ¼ö¼ú ¿¬±âÀÇ À§Ç輺°ú Á¶Á÷ È­»ó¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÇ·á ½Ã½ºÅÛÀº º¸´Ù ¾ÈÀüÇÑ ´ëü ÀÇ·á·Î ÇâÇϰí ÀÖ½À´Ï´Ù. ÇöóÁ Àåºñ´Â Á¶Á÷ ±«»ç¸¦ ¾ïÁ¦ÇÏ°í ¼ö¼ú ½Ã ¹ß»ýÇÏ´Â ¿¬±â¸¦ ÃÖ¼ÒÈ­ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î Á÷¾÷Àû ³ëÃâ°ú ȯÀÚ °á°ú¸¦ ¿ì·ÁÇÏ´Â ¿Ü°úÀÇ»çµé »çÀÌ¿¡¼­ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °ãÄ¡¸é¼­ ÇöóÁ ¼ö¼ú ½ÃÀåÀº Á¤¹Ð ¼ö¼ú ±â¼úÀÇ ´ÙÀ½ ½Ã´ëÀÇ Áß½ÉÀÌ µÉ ż¼¸¦ °®Ãß°í ÀÖÀ¸¸ç, ±× º¸±ÞÀº ÇöÀçÀÇ ¾Æ¼ºÀ» ÈξÀ ¶Ù¾î³ÑÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç°(´ºÆ®·² ÇöóÁ ¼ö¼ú ½Ã½ºÅÛ, ÇöóÁ ÀýÁ¦ ½Ã½ºÅÛ, Àú¿Â ÇöóÁ ¼ö¼ú ½Ã½ºÅÛ), ¿ëµµ(ÀýÁ¦ ¿ëµµ, ÀϺÎÀýÁ¦ ¿ëµµ, ¹Ú¸® ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Àü¹® Ŭ¸®´Ð ÃÖÁ¾ ¿ëµµ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, º´¿ø ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå°ú °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Plasma Surgery Market to Reach US$91.0 Million by 2030

The global market for Plasma Surgery estimated at US$69.5 Million in the year 2024, is expected to reach US$91.0 Million by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Neutral Plasma Surgery System, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$60.2 Million by the end of the analysis period. Growth in the Plasma Ablation System segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$18.9 Million While China is Forecast to Grow at 8.4% CAGR

The Plasma Surgery market in the U.S. is estimated at US$18.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.0 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Plasma Surgery Market - Key Trends & Drivers Summarized

Exploring the Transformational Role of Cold and Thermal Plasma in Modern Surgical Practices

What Makes Plasma Surgery an Emerging Frontier in Minimally Invasive Interventions?

Plasma surgery is revolutionizing the surgical landscape through the application of ionized gas-plasma-to perform precise tissue manipulation, coagulation, and ablation. Two principal technologies dominate this field: cold atmospheric plasma (CAP) and thermal plasma systems. Cold plasma operates at room temperatures, allowing for non-thermal applications in delicate surgeries like ophthalmology and dermatology. Thermal plasma, on the other hand, produces higher temperatures suitable for coagulation and ablation in areas like orthopedic and ENT procedures. These distinct modalities offer precise tissue targeting without extensive collateral damage, setting plasma systems apart from electrocautery, laser, and radiofrequency alternatives. Unlike traditional energy-based devices, plasma scalpels and ablators deliver a significantly higher degree of surgical precision and reduced thermal spread. For instance, in procedures such as tonsillectomies and adenoidectomies, plasma scalpels have been shown to reduce intraoperative bleeding and postoperative pain. The ability to combine cutting and coagulation in a single step is gaining traction in ENT, neurosurgery, gynecology, and urology. Furthermore, advancements in bipolar plasma technology are enabling real-time modulation of energy delivery based on tissue impedance, further enhancing intraoperative control. Clinical trials continue to highlight improved wound healing, reduced inflammatory response, and faster recovery time-all of which are encouraging broader adoption.

Where Are Plasma Surgery Systems Finding the Greatest Market Penetration?

The clinical adoption of plasma surgical devices is being driven by their compatibility across a wide range of surgical specialties. Otolaryngology (ENT) represents one of the earliest adopters of plasma technology, where procedures such as turbinate reduction, tonsillectomy, and polypectomy leverage the technique’s low-bleed profile. Similarly, in gynecology, plasma-based endometrial ablation and laparoscopic interventions are rising, especially for patients with contraindications to thermal damage. Another high-growth area is orthopedic and spinal surgery, where plasma wands enable efficient removal of soft tissue and precise coagulation around sensitive neural structures. The oncology segment is beginning to explore cold plasma applications for tumor reduction, particularly in superficial cancers like basal cell carcinoma and squamous cell carcinoma. Moreover, in neurosurgery, where surgical accuracy is paramount, cold plasma systems are being trialed to dissect tumors in eloquent brain areas while preserving surrounding tissue integrity. The aesthetic surgery and dermatology sectors are also rapidly integrating plasma pens for skin resurfacing, acne scar treatment, and non-ablative skin rejuvenation-especially in clinics focusing on scarless, outpatient procedures.

Regionally, North America leads the global plasma surgery market due to advanced healthcare infrastructure, high procedural volume, and the presence of prominent players such as Medtronic, Smith & Nephew, and Bovie Medical. Europe follows closely, particularly in Germany and the UK, where ENT and gynecological use cases have been mainstreamed. The Asia-Pacific market, although nascent, is showing strong potential driven by increasing surgical volumes, a growing private hospital base, and rising interest in non-thermal plasma applications in dermatology and oncology. Countries like South Korea and India are emerging as early adopters of portable and handheld plasma devices due to cost constraints and demand for minimally invasive treatments.

How Is Innovation Shaping the Future of Plasma-Based Surgical Technologies?

Technological advancement is a key pillar supporting the expansion of plasma surgery applications. Recent breakthroughs include the miniaturization of plasma devices, enabling their integration into robotic surgical arms and flexible endoscopic platforms. This development is particularly critical for accessing hard-to-reach anatomical areas, including intracranial, bronchial, and gastrointestinal cavities. The coupling of cold plasma systems with fiber-optic delivery modules has allowed for safer, more targeted application of plasma in endoluminal surgeries, such as endobronchial ablation and transnasal interventions. Moreover, research is progressing rapidly on plasma-activated media (PAM), where biological fluids are ionized and then applied to tissue, offering a promising approach for sterilization and cancer cell apoptosis without direct contact. Integration of AI and real-time analytics is also beginning to emerge in next-generation plasma systems. Algorithms that adapt energy output based on tissue feedback are enhancing safety and reducing intraoperative guesswork. On the material science front, the development of biocompatible electrode coatings and high-frequency modulation circuits is enabling greater control over arc formation and power density, essential for expanding indications.

In addition to hardware innovation, software-driven advancements in user interface and procedural templates are making plasma devices more surgeon-friendly. Devices now offer touchscreen controls, pre-programmed procedure modes, and integration with hospital EHRs. These features are streamlining device training, standardizing procedural outcomes, and expanding access in outpatient settings. Meanwhile, cross-industry collaborations between device manufacturers, clinical researchers, and academic institutions are helping to establish more robust clinical protocols and safety benchmarks, facilitating faster regulatory approvals and accelerating market entry in emerging economies.

What Are the Key Market Catalysts Fueling the Rise of Plasma Surgery Worldwide?

The growth in the global plasma surgery market is driven by several factors that span technological, clinical, regulatory, and economic domains. One of the primary growth drivers is the increasing preference for minimally invasive surgical (MIS) techniques across nearly all surgical specialties. Surgeons and healthcare providers are shifting toward low-trauma interventions that reduce hospitalization time, complications, and overall procedural costs-areas where plasma surgery is particularly well-suited. Plasma systems allow for effective hemostasis, enhanced visibility, and shorter recovery times, all of which are critical to accelerating surgical throughput and improving patient satisfaction. Another driver is the ongoing global expansion of outpatient and ambulatory surgical centers (ASCs), especially in the U.S., Japan, and India. These settings demand compact, multifunctional tools with high safety margins-requirements that plasma devices meet effectively. In addition, increasing geriatric populations and rising prevalence of chronic conditions such as cancer, uterine fibroids, nasal polyps, and osteoarthritis are spurring demand for less invasive yet highly effective surgical treatments. Plasma surgery is emerging as a go-to option in such contexts, especially where conventional modalities pose excessive risk or require extended rehabilitation. Market momentum is also supported by more favorable regulatory landscapes and reimbursement frameworks. For instance, certain cold plasma applications in dermatology and ENT surgeries are now covered by public and private insurers in the U.S. and Germany. Furthermore, strategic investments by leading device manufacturers into R&D, product training, and global distributor networks are facilitating deeper market penetration. Collaborations with academic institutions for clinical validation are enabling faster integration of plasma technologies into standard-of-care practices.

Finally, growing awareness of surgical smoke hazards and tissue charring associated with traditional electrosurgery is nudging healthcare systems toward safer alternatives. Plasma devices, known for reduced tissue necrosis and minimal surgical plume, are gaining preference among surgeons concerned with occupational exposure and patient outcomes. As these factors coalesce, the plasma surgery market is poised to become a central player in the next era of precision surgical technologies, with adoption likely to extend far beyond its current strongholds.

SCOPE OF STUDY:

The report analyzes the Plasma Surgery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Neutral Plasma Surgery System, Plasma Ablation System, Cold Plasma Surgical System); Application (Ablation Application, Resection Application, Dissection Application); End-Use (Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use, Hospitals End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â